Stocksigma LogoStocksigma Logo

AstraZeneca Pharma India to Launch Breast Cancer Drug Datverzo in Nov'26

AstraZeneca Pharma India Limited announced it will launch Datopotamab Deruxtecan (brand name: Datverzo) in India in Nov'26, following import and market

AstraZeneca Pharma India to Launch Breast Cancer Drug Datverzo in Nov'26

AstraZeneca Pharma India Ltd 路 Others (Uncategorized) 路 07 Nov 2026, 5:49 pm

AstraZeneca Pharma India to Launch Breast Cancer Drug Datverzo in Nov'26 AstraZeneca Pharma India Limited announced it will launch Datopotamab Deruxtecan (brand name: Datverzo) in India in Nov'26, following import and market permissions received from the DCGI in Dec'25. Datverzo is approved for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have undergone prior endocrine-based therapy and chemotherapy.

Original exchange filing (PDF)

More announcements from AstraZeneca Pharma India Ltd

All AstraZeneca Pharma India Ltd announcements